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Abstract
Background: Spinal muscular atrophy (SMA type I, II and III) is an autosomal recessive neuromuscular disorder
caused by mutations in the survival motor neuron gene (SMN1). SMN2 is a centromeric copy gene that has been
characterized as a major modifier of SMA severity. SMA type I patients have one or two SMN2 copies while most
SMA type II patients carry three SMN2 copies and SMA III patients have three or four SMN2 copies. The SMN1 gene
produces a full-length transcript (FL-SMN) while SMN2 is only able to produce a small portion of the FL-SMN
because of a splice mutation which results in the production of abnormal SMNΔ7 mRNA.
Methods: In this study we performed quantification of the SMN2 gene copy number in Russian patients affected
by SMA type II and III (42 and 19 patients, respectively) by means of real-time PCR. Moreover, we present two
families consisting of asymptomatic carriers of a homozygous absence of the SMN1 gene. We also developed a
novel RT-qPCR-based assay to determine the FL-SMN/SMNΔ7 mRNA ratio as SMA biomarker.
Results: Comparison of the SMN2 copy number and clinical features revealed a significant correlation between
mild clinical phenotype (SMA type III) and presence of four copies of the SMN2 gene. In both asymptomatic cases
we found an increased number of SMN2 copies in the healthy carriers and a biallelic SMN1 absence. Furthermore,
the novel assay revealed a difference between SMA patients and healthy controls.
Conclusions: We suggest that the SMN2 gene copy quantification in SMA patients could be used as a prognostic
tool for discrimination between the SMA type II and SMA type III diagnoses, whereas the FL-SMN/SMNΔ7 mRNA
ratio could be a useful biomarker for detecting changes during SMA pharmacotherapy.
Background
Spinal muscular atrophy (SMA) is an autosomal reces-
sive neuromuscular disorder characterized by degenera-
tion of alpha motor neurons in the anterior horns of the
spinal cord. SMA is one of the leading genetic causes of
infant mortality, with an incidence of about 1 in 8000
live births and with a carrier frequency of about 1 in 40
[1]. SMA subdivides into types I, II, and III based on
age of onset and clinical severity [2], and are all caused
by mutations within the survival motor neuron gene
(SMN1) located on chromosome 5q13. Approximately
95 percent of these patients have a homozygous deletion
of exon 7 in the SMN1 gene. Small intragenic mutations
have been found in the remaining affected individuals
who do not lack both copies of SMN1 [3]. SMN2 is an
almost identical centromeric SMN1 copy, with 8 nucleo-
tide substitutions: five in the introns and three in exons
6, 7 and 8 [4]. Single-nucleotide transition of C to T at
position 6 of SMN2 exon 7 does not change an amino
acid, but causes disruption of a splicing enchancer site,
which results in mRNA lacking exon 7 (SMNΔ7) [5].
Most of the SMN1 transcripts are full-length whereas
t h em a j o r i t yo ft h eSMN2 transcripts lack exon 7. Con-
sequently, SMN2 is not able to compensate for the loss
of exon 7 in SMN1 of the SMA patients. Nevertheless,
the SMN2 copy number is considered to be a modifying
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patients have one or two SMN2 copies while most SMA
type II patients carry three SMN2 copies and SMA III
patients have three or four SMN2 copies [6-8].
The SMN1 gene normally produces full-length SMN
mRNA, whereas conversely approximately only 20 percent
of the full-length SMN mRNA is produced from the SMN2
gene [9]. This observation suggests a potential significant
distinction in the FL-SMN transcript levels among healthy
individuals, carriers and different types of SMA patients.
However, there are conflicting results concerning the differ-
ences between the levels of FL-SMN and Δ7SMN mRNA
in SMA patients, carriers and healthy people [10-12].
Decreased FL-SMN expression has been shown only for
type I SMA patients. Fluctuations in transcript levels
throughout drug treatment were also observed in recent
clinical trials [13]. However, it remains unclear whether the
levels of FL-SMN and Δ7SMN mRNA are associated with
the type of disease or the copy number of SMN2.
In this study, we performed SMN2 gene copy number
determination for patients affected by SMA type II and
III (42 and 19 patients, respectively). We also present
two case-reports: one SMA type III patient and his
asymptomatic sister, and one SMA type II patient and
his asymptomatic mother being homozygous for the
absence of the SMN1 gene. To evaluate the importance
of the FL-SMN/SMNΔ7 mRNA ratio as a SMA biomar-
ker, we carried out RT-qPCR based quantification of
FL-SMN and SMNΔ7 mRNA levels in a small group of
type II and III SMA patients.
Methods
Patients
Genetic analysis was approved by the ethics committee at
Ott’s Institute of Obstetrics and Gynecology RAMS. The
adult patients and parents of all children gave written
informed consent to the diagnostic procedures. Molecular
testing for deletion in the SMN1 gene was performed in
190 Russian families from the North-Western region of
Russia with SMA including 172 affected individuals, 243
parents, 14 siblings and 44 other relatives (totally 301 rela-
tives were tested). SMN2 gene copy number determination
was performed for 42 type II SMA-patients and 19 type III
SMA-patients. SMN2 gene copy number was also deter-
mined in several clinically healthy family members includ-
ing four parents, two siblings and one grandmother. Blood
samples for the determination of SMN gene expression
were obtained from five SMA patients, one SMA carrier
and two healthy individuals (Table 1).
DNA isolation
Genomic DNA was extracted from peripheral blood leu-
kocytes of SMA patients, their relatives and healthy
individuals using the phenol-chloroform method [14].
Polymerase chain reaction - restriction fragment length
polymorphism (PCR-RFLP) and single strand conformation
analysis (SSCA)
All SMA patients and their relatives were tested for
SMN1 exon 7 and 8 deletions by means of SSCA (for
exon 7) and PCR-RFLP analysis (for exon 8). PCR-RFLP
and SSCA methods were performed as described pre-
viously [15].
Real-time PCR for SMN2 gene copy number
determination
We applied the TaqMan real-time PCR method as pre-
viously described [16]. The DNA sample of the SMA
patient with four SMN2 gene copies was used as stan-
dard in all amplification reactions. The presence of four
copies was established earlier using reference DNA sam-
ples kindly provided by prof. B. Wirth (Institute of
Human Genetics, University of Cologne). In each run
we also used DNA samples from SMA patients with
two and three copies as additional standards. The b-glo-
bine (HBB) gene was used as a reference locus in line
with previously published primers and probe [17].
PCR was performed using the thermocycler Rotor-
Gene 3000 (Corbett Life Science, Australia). PCR was
carried out in a total volume of 20 μl and contained 10-
Table 1 FL-SMN and Δ7 SMN baseline transcript measurement in SMA patients, SMA carrier and control individuals
Sex SMA type Number of SMN2
copies
Relative level of FL-SMN
transcript
Relative level of Δ7 SMN
transcript
FL-SMN/Δ7SMN
ratio
1 M III 3 2.6 2.11 1.23
2 M II 3 0.85 1.24 0.69
3 F II 3 1.74 0.83 2.09
4 F III 4 3.23 2.78 1.16
5 F asymptomatic 4 1.39 2.48 0.56
F carrier 4 1.40 2.02 0.69
F control 2 3.25 1.05 3.10
M control 1 3.87 0.53 7.3
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Page 2 of 9160 ng of genomic DNA, 1 μl of each primers (1 A260 o.
u.) (Syntol, Russia), 2 μlo f2μM SMN2 MGB (Minor
Groove Binder) probe (Applied Biosystems, USA), 2 μl
of 2 μM of HBB probe (Syntol, Russia), 2.5 μlo f2m M
dNTP mix (Fermentas, Lithuania), 2 μlo f2 5m M
MgCl2,2μl of 10× polymerase buffer and 0.3 μlo fT a q
DNA polymerase (Sileks, Russia).
We amplified 160 ng, 80 ng, 40 ng, 10 ng of standard
DNA and 50 ng of each tested DNA in one run. PCR
conditions were as follows: 94°C for 10 minutes, 40 cycles
consisting of 95°C for 20 seconds, 60°C for 1 minute.
Data was analyzed by Rotor-Gene version 6.1.71 soft-
ware. All samples were measured three times and a final
result was inferred by averaging data. The value ranges
for two, three and four SMN2 gene copy number were
estimated. Confidence of differences between the values
range was confirmed using unpaired Student’s t-test (p <
0.01), using GraphPad Prism v5.03 (GraphPad, USA).
RNA isolation and cDNA synthesis
Peripheral blood was collected into Vacuette tubes
(Greiner Bio One, USA). 2 ml of blood was lysed with
hemolysis buffer (8.4 g/l NH4Cl) for 30 minutes. The
leukocyte phase was obtained by centrifuging the blood
sample at 1500 rpm for 20 minutes. Collected cells were
stored in RNAlater solution (Quiagen, Germany) for up
to twelve months at -80°C. RNA isolation was per-
formed simultaneously from all samples using RiboPure
- Blood Kit (Applied Biosystems). For cDNA synthesis
12 μl of each RNA sample was incubated with 0.5 μlo f
25 mM dNTP mix (Fermentas) and 0.5 μl of hexapri-
mers (50 A260 o.e.) (Roche) at 65°C for 5 minutes. Sam-
ples were kept on ice for 1 minute. 4 μl of 5× FS buffer,
2 μl 0, 1 M DTT and 1 μl of M-MLV Reverse transcrip-
tase (Invitrogen) were added to samples. Reactions were
incubated at 25°C for 10 minutes, then at 37°C for 1
hour, then at 95°C for 15 minutes.
Quantitative reverse transcriptase real-time PCR
The assay was carried out on a MyiQ thermal cycler
(Bio-Rad Laboratories, Sweden), using 96-well plates.
The primers were designed using Beacon Primer Design
4.0 software (Premier Biosoft, USA). Primers for full-
length SMN transcripts amplification were forward 5’-
CTGATGCTTTGGGAAGTAT-3’, reverse 5’-GCCAG-
CATTTCTCCTTAA-3’,f o rΔ7SMN transcripts amplifi-
cation were forward 5’-GTCCAGATTCTCTTGA
TGAT-3’, reverse 5’-GCCAGCATTTCCATATAATAG-
3’. We also amplified two reference genes - glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) and histone
H3b. Primers sequences were following: for GAPDH
locus forward 5’-CGCCAGCCGAGCCACATC-3’,
reverse 5’-CGCCCAATACGACCAAATCCG-3’;f o rH3b
locus forward 5’-ATCCGCCGCTACCAAAAG-3’,
reverse 5’-CGAAGATCGGTCTTGAAGTC-3’. Reactions
were performed in the final volume of 20 μl and con-
tained 5 μlo fc D N A( 5n g / μl), 0.05 μlo fe a c hp r i m e r
(100 pmol/μl), 1 μlD M S O ,0 . 5μl of SYBR GREEN I
(1:50000; Invitrogen, Sweden) in TE buffer (pH 7.8), 0.2
μl of 25 mM dNTP mix (Fermentas), 2 μl 10× buffer,
1.6 μlo f5 0m MM g C l 2,0 . 0 8μl of Taq DNA polymer-
ase (Biotools, Spain). Cycling conditions were as follows:
3-minutes initial denaturation step, followed by 40
cycles of 95°C for 20 seconds, 20 seconds at 55-60.5
(optimal annealing temperature of primers), 30 seconds
at 72°C. Fluorescence was measured after the elongation
phase. 81 cycles of 10 sec at 55°C with increasing incre-
ments of 0.5°C per cycle was performed for melting
curve analysis. A negative control for each primer’s pair
was included on each plate. All samples were run in
duplicate. MyiQ software v 1.04 (Bio-Rad Laboratories,
Sweden) was used to process real-time PCR data and
determine threshold cycle (Ct) values. Melting curve
analysis was performed to confirm that only one pro-
duct was amplified and there were not any products in
negative controls. LinRegPCR was used to calculate PCR
efficiencies for each sample. Outliers were excluded and
the average PCR efficiency for each primers pair was
calculated using Grubbs’ test for outliers (GraphPad,
USA). Relative quantities with standard deviations were
calculated using the delta Ct method. Normalization
was performed via the GeNorm method using expres-
sion levels of GAPDH and H3b.
Results
Quantification of SMN2 gene copy number in patients
with spinal muscular atrophy
I nt h i ss t u d yw ep e r f o r m e dSMN2 dosage analysis in 42
type II-, and 19 type III SMA patients. The SMN2 gene
copy number was determined using a real-time PCR quan-
tification method with MGB-TaqMan probes [16]. DNA
samples from the SMA patients carrying between one and
four SMN2 copies were used as controls for the analysis.
We found that the sample-to-sample variation after
relative quantification analysis for the two SMN2 gene
copies per genome was in the range of 0.73-1.32; for
three copies per genome it was in range of 1.27-1.72;
and for four copies per genome it was in range of 1.71-
2.2. These values were multiplied by a factor of two to
o b t a i nt h eg e n ec o p yn u m b e r .T h e s er e s u l t sa r ei n
agreement with previously published data obtained by
real-time PCR approaches using TaqMan or LightCycler
techniques [8,16,18].
The results of the SMN2 gene copy number quantifi-
cation in the SMA patients are presented in Figure 1. It
can be seen that most of the SMA type II patients have
three copies of SMN2 gene per genome (76.2%), whereas
two and four copies were found in equal numbers of the
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three copies of SMN2 gene for lesser number of patients
(57.9%) while four copies were found in 7 of 19 patients
(36.8%). It should be noted that we found one patient
affected by SMA type III bearing two copies of the
SMN2 gene (5.3%). The average SMN2 copy number in
type II and type III patients was found to be similar (3.0
± 0.49 vs 3.32 ± 0.58; p > 0.01). We were not able to
reveal significant differences between the SMA type II
and III patients bearing two copies of the SMN2 gene (5
of 42 type II patients and one of 19 type III patients) (p
> 0.05). This was likely due to the low number of indivi-
duals in each group. The difference in frequency of
three copies of SMN2 gene between type II and III
patients was also not found to be significant (32 of 42
type II patients and 11 of 19 type III patients) (p >
0.05). However, we did find a significant difference in
the frequency of having four SMN2 gene copies between
type II and type III patients (p = 0.0233, c2 = 5.148).
Asymptomatic family members lacking both copies of the
SMN1 gene
We carried out routine molecular genetic diagnoses in
301 clinically healthy members of Russian SMA families,
including obligatory deletion carriers such as parents
and siblings who have a chance of being heterozygous
carriers, and other relatives. In each family, deletions of
exons 7 and 8 of SMN1 and SMN2 were determined by
means of SSCP analysis and RFLP analysis [15]. As a
result of the diagnosis, we revealed two families of
asymptomatic individuals who were homozygous for the
absence of exons 7 and 8 of SMN1. Therefore, the pre-
valence of asymptomatic cases in Russian families may
be estimated at approximately 0.7% of first-degree rela-
tives of SMA patients.
Family 1 (no. S265)
There were two half-siblings in family 1 (Figure 2a). The
younger brother was affected with SMA type II. The
diagnosis was confirmed by molecular testing of dele-
tions of the SMN1 exon 7 and 8. Molecular diagnostics
showed a heterozygous deletion carrier state in a healthy
stepbrother (III:1). The father (II:2) of the affected boy
(III:2) was found to be heterozygous for the deletion,
whereas the 45 year old mother (II:1) carried a biallelic
deletion of exon 7 and 8 of SMN1. Quantification of
SMN2 gene copy number in the members of family 1
allowed us to explain the absence of SMA symptoms in
the mother. It was shown that the father and the SMA
type II affected son carried two copies of SMN2.T h r e e
copies of SMN2 were found in the healthy stepbrother.
Figure 1 Frequencies (%) of the SMN2 gene copy numbers in patients with SMA type II and III.*-c2-test was used for the comparison
of SMN2 gene copy number between type II and type III patients (p = 0.0233, c2 = 5.148).
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in the asymptomatic mother.
Family 2 (no. S280)
There were two siblings in family 2 (Figure 2b). The
younger brother was affected with SMA type IIIb. The
actual SMA symptoms debuted at age 21. Molecular
diagnostics confirmed the original diagnosis and
revealed a homozygous deletion of exon 7 and 8 of
SMN1. The same analysis showed biallelic deletion in a
healthy 25 years old sister (II:1). Both parents were
found to be deletion carriers. The number of SMN2
gene copies was determined in the members of family 2.
We found two copies of SMN2 in the father and four
copies in the mother. The analysis revealed four copies
of SMN2 gene in the proband and his asymptomatic
sister.
Measurement of SMN baseline expression levels
I nt h ep r e s e n ts t u d yw eh a v ed e v e l o p e dan o v e la s s a y
based on real-time PCR, which allows the quantification
Figure 2 Pedigrees of spinal muscular atrophy (SMA) families with biallelic absence of the SMN1 gene in unaffected subjects. (a) family
1, (b) family 2; circles represent females, squares represent males, black symbols represent biallelic SMN1 absence in affected individuals, dot
symbols represent heterozygous SMA carriers, vertical line symbols represent biallelic SMN1 absence in unaffected individuals.
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uated by characterization of the SMN baseline expres-
sion level in blood samples taken from eight individuals
- two patients affected by SMA type II, two patients
affected by SMA type III, one asymptomatic individual,
one SMA carrier and two healthy controls (Table 1).
The assay was used to investigate whether FL-SMN
mRNA levels are reduced in the patients compared with
healthy individuals.
Baseline level of the FL-SMN mRNA expression varied
greatly in the SMA patients in range 0.85 - 3.23 (Figure
3a). Mean ± SEM was found to be 1.97 ± 0.43. In addi-
tion, sustained variability was observed in the baseline
level of SMNΔ7 mRNA expression in range 0.83 - 2.78.
Mean ± SEM was found to be 1.89 ± 0.37 (Figure 3b).
Thus the mRNA levels of FL-SMN and SMNΔ7i nt h e
control subjects overlapped with the values for the SMA
patients, which represented similar, slightly lower (for
FL-SMN) or slightly higher (for SMNΔ7) values. It is
suggested that the similarity in expression levels
between control individuals and the patients may be due
to increased SMN2 gene copy number. Three SMA
patients from the studied cohort were found to have
three SMN2 gene copies whereas the other two had four
SMN2 gene copies (Table 1).
Previously it has been shown that FL-SMN/SMNΔ7
mRNA ratio can be used in the SMN expression analysis
in order to avoid confounding effects of FL-SMN and
SMNΔ7 mRNA level fluctuations [13]. Taking this
approach we analysed FL-SMN/SMNΔ7 mRNA ratio in
the patients and control individuals. It can be seen in Fig-
ure 3c that the quantification of FL-SMN/SMNΔ7 mRNA
ratio revealed a difference between SMA patients and
healthy controls. This parameter varied in the range of
0.56 - 2.10. The mean ± SEM was found to be 1.15 ± 0.27.
Discussion
By comparing the SMN2 gene copy number and clinical
features of patients with SMA, we have revealed, for the
first time in a Russian population, a significant correla-
tion between mild clinical phenotype (SMA type III)
and a presence of four copies of SMN2 gene. The
SMN2 gene is considered to be a major modifier of
SMA. Despite the presence of the splice mutation in
exon 7, the SMN2 gene is able to produce up to 10% of
FL-SMN mRNA. Multiplication of SMN2 gene copies in
the genome of SMA patients can therefore lead to varia-
bility in the SMA phenotype [8,19,20]. Quantification of
the SMN2 gene copy number has been suggested to be
an important prognostic criterion for SMA diagnosis
[8]. In our study, we suggest that the SMA patients
bearing four copies of the SMN2 gene can be considered
as type III patients rather than the II type. This is
because, according to the data obtained (Figure 1) 12
percent of SMA type II patients were found to have
four copies. Thus, the specificity of the SMN2 gene copy
number as a prognostic tool can be estimated as an 88
percent risk for a child with four SMN2 gene copies to
have SMA type III. For example in a previous study, the
risk of developing SMA type III in a child with four
SMN2 copies was estimated to be 83.6 percent [8]. This
finding is in concordance with previously published data
concerning genotype-phenotype correlation in SMA
patients [8,19]. However, it should be noted that this
genotype-phenotype correlation is not absolute and can
be influenced by modifying genes, point mutations or
conversions of SMN2 [8]. Our results suggest that the
SMN2 gene copy measurements in SMA patients can be
used as a prognostic tool for discrimination between the
SMA type II and SMA type III diagnosis.
The importance of the SMN2 gene copy number
determination can be further illustrated by our findings
in families that have unaffected relatives with a homozy-
gous loss of the SMN1 gene. Being an exceptionally rare
event, homozygous deletion of SMN1 e x o n7a n d8i n
unaffected relatives of SMA patients has been reported
several times in American, German and Polish SMA
families [21-24]. In this study we were able, for the first
Figure 3 SMN gene baseline expression variability in SMA patients and healthy individuals. (a) the variability of baseline full-length SMN
transcript level; (b) the variability of baseline SMNΔ7 transcript level; (c) the variability of baseline FL-SMN/SMNΔ7 mRNA ratio.
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Russian SMA families. In both of the cases of asympto-
matic loss of the SMN1 gene the influence of SMN2 copy
number on the SMA severity was demonstrated. In family
1, we see that the higher SMN2 copy number completely
abolishes the SMA phenotype in a mother of a child
severely affected by SMA type II. The second case demon-
strates that four copies of SMN2 results in a very mild
SMA phenotype in a man homozygous for absence of
SMN1. Conversely, no symptoms were observed in the sis-
ter who had the same genotype. This can only be
explained by influence on SMA phenotype by genetic fac-
tors other than the SMN2 gene copy number. Family 2
represents a rare case of siblings with identical SMN1
mutations, identical SMN2 copy number, but discrepancy
in phenotype. This finding suggests that there are addi-
tional factors, such as mutations, genetic and epigenetic
modifiers to influence the severity of SMA. For instance,
higher expression of plastin 3 has been observed in asymp-
tomatic SMN1-deleted females, which has been shown to
rescue axon growth defects in animal models for SMN1
deficiency [25]. The c.859G > C substitution in SMN2
gene has also been suggested as a positive modifier of
SMA phenotype [26]. This substitution forms a new exo-
nic splicing enhancer that increases the amount of full-
length SMN2 mRNA. The c.859G > C variant was
detected in SMA patients discordant for the disease sever-
ity and the SMN2 gene copy number [27]. Variations in
the disease progression between SMA patients with identi-
cal number of SMN2 gene can also be explained by differ-
ences in DNA methylation. Methylation of a small part of
CpG islands in the region of upstream and downstream of
the translational SMN2 start site has been identified to
correlate with the disease severity [28]. Gender could be
suggested as SMA severity modifiyng factor; to date most
of asymptomatic persons with homozygous loss of the
SMN1 gene are females [29].
The number of SMN2 gene copies in SMA patients
has been studied intensively in several previous studies
including different populations. However, to date no
previous publications concerning Russian populations
have been analysed. Here we present SMN2 dosage ana-
lysis in 61 SMA patients who originated from North-
Western Russia. Individuals affected by SMA type II and
III were subjected to the analysis because it has been
suggested that their milder phenotype is a result of an
increase of the SMN2 gene copy number. The distribu-
tion of SMN2 gene copy number observed in the SMA
patients from the northwestern region of Russia was
compared with the distributions reported for the SMA
patients from some other populations. We did not
observe any difference in SMN2 gene copy number dis-
tribution between Russian and German, Spanish and
Vietnamese SMA patients [8,18,19].
Recent clinical trials on SMA treatment by histone
deacetylation inhibitors such as valproic acid and phe-
nylbutyrate have revealed some promising results. These
trials focused on children with SMA types II and III
[13,30-32]. Our clinical experience, from a study of how
valproic acid can influence the symptoms of SMA, high-
lights the necessity to elaborate with reliable and effi-
cient biomarkers on the progress of the SMA treatment
[33].
In the present study we developed a novel RT-qPCR-
based assay to determine baseline level of FL-SMN and
SMNΔ7 mRNA expression in SMA patients and normal
individuals. The assay was evaluated on a small group of
type II and III SMA patients. A sustained variability in
the relative amount both FL-SMN and SMNΔ7t r a n -
scripts among these patients was found, which prevents
the use of these parameters as biomarkers of SMA treat-
ment. The mRNA levels of FL-SMN and SMNΔ7i nt h e
control subjects overlapped with the values for the SMA
patients, which represented similar or slightly lower (for
FL-SMN) or slightly higher (for SMNΔ7) values. Our
data on the SMN baseline expression levels are similar
to the results published by others. For example, in intial
studies of SMN2 gene expression in SMA patients an
overlap between SMN/GAPDH ratios in patients and
controls was found [34]. In the study of Simard and co-
authors, FL-SMN mRNA and SMNΔ7m R N As i g n i f i -
cantly varied in the range of 0.30 - 1.22 and 0.61 - 2.97
[11]. Absolute quantification of FL-SMN mRNA in
SMA patients revealed a broad range of variability -
33.75 - 123.00 [12]. The relatively high level of SMNΔ7
mRNA found in our patients compared to controls is an
interesting feature that has also been described pre-
viously [10,35]. The role of SMNΔ7 mRNA in the devel-
opment of SMA is unclear. Higher SMNΔ7 mRNA level
has been shown to negatively influence the SMA devel-
opment via neurotoxicity mediated by a pro-apoptotic
action of the truncated SMN protein [36]. However, an
increased expression of SMNΔ7 mRNA has been sug-
gested to lead to a higher life expectancy in an SMA
mouse model [37].
In accordance with the literature, FL-SMN/SMNΔ7
mRNA ratio was used in our analysis in order to avoid
confounding effects of FL-SMN and SMNΔ7m R N A
level fluctuations [13]. It can be seen in Figure 3c that
the quantification of FL-SMN/SMNΔ7m R N Ar a t i o
revealed a difference between SMA patients and healthy
controls. This parameter varied in the range of 0.56 -
2.10 and does not overlap with control values. Thus, we
suggest that the FL-SMN/SMNΔ7 mRNA ratio could be
used as a diagnostic biomarker for discrimination
between SMA patients and normal individuals. It could
also be used to determine the effect of the SMA treat-
ment by drugs which are able to correct exon 7 splicing,
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that the mechanism of action of some histone deacetyla-
tion inhibitors is complex, for example it seems that val-
proic acid affects both SMN gene expression and
splicing [38]. However, the clear difference in FL-SMN/
SMNΔ7 mRNA ratio between SMA patients and normal
individuals, as found in this study and also shown by
others, suggests the usefulness of this biomarker for
detecting changes during SMA pharmacotherapy.
Conclusions
The SMN2 gene copy quantification in SMA patients
can be used as a prognostic tool for discrimination
between the SMA type II and SMA type III diagnosis. A
novel RT-qPCR-based assay can be used to determine
the FL-SMN/SMNΔ7 mRNA ratio. This ratio could be a
diagnostic biomarker for monitoring changes during
SMA pharmacotherapy.
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